首页> 外文期刊>Acta Cytologica: The Journal of Clinical Cytology and Cytopathology >Tissue microarrays for testing molecular biomarkers of cervical intraepithelial neoplasia: feasibility study.
【24h】

Tissue microarrays for testing molecular biomarkers of cervical intraepithelial neoplasia: feasibility study.

机译:用于检测宫颈上皮内瘤变的分子生物标志物的组织芯片:可行性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To test the possibility of creating tissue microarrays of pre-malignant lesions of the cervix. STUDY DESIGN Paraffin-embedded blocks of 240 cervical tissue specimens were sampled. Lesions from benign squamous and glandular epithelium through various grades of cervical intraepithelial neoplasia (CIN) to frank carcinoma of squamous and glandular origin were cored with a 0.6-mm needle and arrayed in 4 tissue blocks. Sections of these blocks were stained with hematoxylineosin (H-E) and evaluated as to adequacy of tissue cores, representativity of the material and correspondence to the original diagnosis. Immunohistochemical staining with p16 and a novel marker C4.8(4/2/#1) was performed. RESULTS: In > 80% of cases sufficient material from the lesion could be obtained. No or inadequate material was seen in 6% of cases. The core sample did not correspond to the original diagnosis in 12% of cases. The reason was mainly a discrepancy in the grade of the CIN. Discrepancies in diagnoses occurred in only premalignant lesions. Immunohistochemical staining could reliably be performed and evaluated on all tissue cores. CONCLUSION: Tissue microarrays of cervical intraepithelial lesions are technically feasible and can be created reliably. The key to success is a careful and repeated comparison of the tissue block with the corresponding H-E section. Tissue microarrays of preinvasive cervical lesions may allow high throughput analysis of emerging molecular biomarkers in cervical carcinogenesis.
机译:目的:测试建立宫颈癌前病变组织芯片的可能性。研究设计抽取240个宫颈组织标本的石蜡包埋块。从良性鳞状上皮和腺上皮通过各种等级的宫颈上皮内瘤变(CIN)到鳞状和腺源性坦白癌的病变均用0.6毫米针刺入中心,并排列成4个组织块。这些块的切片用苏木精(H-E)染色,并评估组织核心是否足够,材料的代表性以及是否与原始诊断相对应。用p16和新型标记C4.8(4/2 /#1)进行免疫组织化学染色。结果:在> 80%的病例中,可以从病变中获得足够的材料。在6%的病例中没有看到或没有足够的材料。在12%的病例中,核心样本与原始诊断不符。原因主要是CIN的等级存在差异。诊断差异仅发生在癌前病变中。免疫组织化学染色可以可靠地在所有组织核心上进行和评估。结论:宫颈上皮内病变的组织芯片在技术上是可行的,并且可以可靠地建立。成功的关键是将组织块与相应的H-E部分进行仔细反复的比较。宫颈浸润前病变的组织微阵列可以对宫颈癌发生中新兴的分子生物标记物进行高通量分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号